VICP Registry Case Source Bundle
Canonical URL: https://vicp-registry.org/case/USCOURTS-cofc-1_22-vv-00879
Package ID: USCOURTS-cofc-1_22-vv-00879
Petitioner: J.S.
Filed: 2022-08-10
Decided: 2024-07-08
Vaccine: influenza
Vaccination date: 2020-10-03
Condition: Guillain-Barre Syndrome (GBS)
Outcome: compensated
Award amount USD: 189510

AI-assisted case summary:
On August 10, 2022, J.S. filed a petition for compensation under the National Vaccine Injury Compensation Program, alleging Guillain-Barré Syndrome (GBS) resulting from an influenza vaccine received on October 3, 2020. The respondent conceded entitlement, agreeing that the petitioner met the criteria for a Table injury. The case proceeded to a damages hearing. Petitioner, then 66 years old, had a pre-vaccination medical history including diabetes, hypertension, hyperlipidemia, and erectile dysfunction. Ten days after receiving the flu and pneumococcal vaccines, he presented to the emergency department with a two-day history of ascending weakness and numbness, progressing to inability to ambulate. He was admitted to the ICU with concern for GBS. A lumbar puncture revealed elevated protein, and his neurologist diagnosed acute demyelinating polyneuropathy, a form of GBS, ordering IVIG. Petitioner was hospitalized for eleven days, receiving IVIG and gabapentin, and experiencing severe pain managed with opioids. He developed an ileus, requiring rectal and nasogastric tubes, and discontinuation of opioids. He was then transferred to an inpatient rehabilitation facility for 32 days. Upon discharge, he continued outpatient physical and occupational therapy for nearly two months. He continued to experience residual weakness, numbness, balance issues, and pain, impacting his lifestyle and hobbies. His pre-existing erectile dysfunction was exacerbated by the GBS, requiring surgical implantation of a penile prosthesis. By March 2022, he was doing well with no restrictions, though he continued to report some weakness and numbness. The public decision does not describe the specific mechanism of injury or name petitioner's counsel or respondent's counsel. Chief Special Master Brian H. Corcoran issued the ruling. The Special Master awarded $178,000.00 for actual pain and suffering, $6,828.80 for lost earnings, and $4,681.77 for unreimbursable expenses, totaling $189,510.57. The award was a lump sum payment in the form of a check payable to the petitioner.

Theory of causation field:
Petitioner J.S. alleged GBS resulting from an influenza vaccine received on October 3, 2020. Respondent conceded entitlement, agreeing Petitioner met the criteria for a Table injury, specifically GBS occurring between three and forty-two days after a seasonal flu vaccination with no apparent alternative cause. The public text does not detail the specific mechanism of injury or name experts. The Special Master awarded $189,510.57, comprising $178,000.00 for pain and suffering, $6,828.80 for lost earnings, and $4,681.77 for unreimbursable expenses. The decision was issued by Chief Special Master Brian H. Corcoran on July 8, 2024. Petitioner's counsel was Elizabeth Kyla Abramson of Maglio Christopher & Toale, P.A., and Respondent's counsel was Sarah Black Rifkin of the U.S. Department of Justice.

Public staged source text:

================================================================================
DOCUMENT 1: USCOURTS-cofc-1_22-vv-00879-0
Date issued/filed: 2023-04-17
Pages: 2
Docket text: PUBLIC ORDER/RULING (Originally filed: 03/17/2023) regarding 23 Ruling on Entitlement. Signed by Chief Special Master Brian H. Corcoran. (tlf) Service on parties made.
--------------------------------------------------------------------------------
Case 1:22-vv-00879-UNJ Document 27 Filed 04/17/23 Page 1 of 2
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 22-0879V
UNPUBLISHED
JERRY SMITH, Chief Special Master Corcoran
Petitioner, Filed: March 17, 2023
v.
Special Processing Unit (SPU);
SECRETARY OF HEALTH AND Ruling on Entitlement; Concession;
HUMAN SERVICES, Table Injury; Influenza (Flu) Vaccine;
Guillain-Barre Syndrome (GBS)
Respondent.
Elizabeth Kyla Abramson, Maglio Christopher & Toale, PA, Washington, DC, for
Petitioner.
Sarah Black Rifkin, U.S. Department of Justice, Washington, DC, for Respondent.
RULING ON ENTITLEMENT1
On August 10, 2022, Jerry Smith filed a petition for compensation under the
National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.2 (the
“Vaccine Act”). Petitioner alleges that he suffered Guillain-Barre Syndrome resulting from
an influenza (“flu”) vaccine received on October 3, 2020. Petition at ¶¶ 6, 35, 36.
Petitioner further alleges that he received the flu vaccine in the United States, his injury
lasted more than six months, and neither Petitioner nor any other party has ever brought
an action or received compensation in the form of an award or settlement for his vaccine-
related injury. Petition at ¶¶ 37, 40-41; Ex. 12. The case was assigned to the Special
Processing Unit of the Office of Special Masters.
1 Because this unpublished Ruling contains a reasoned explanation for the action in this case, I am required
to post it on the United States Court of Federal Claims' website in accordance with the E-Government Act
of 2002. 44 U.S.C. § 3501 note (2012) (Federal Management and Promotion of Electronic Government
Services). This means the Ruling will be available to anyone with access to the internet. In accordance
with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information,
the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that
the identified material fits within this definition, I will redact such material from public access.
2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease
of citation, all section references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C.
§ 300aa (2012).

Case 1:22-vv-00879-UNJ Document 27 Filed 04/17/23 Page 2 of 2
On March 17, 2023, Respondent filed his Rule 4(c) report in which he concedes
that Petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report at
1. Specifically, Respondent agrees that “petitioner has satisfied the criteria set forth in the
recently revised Vaccine Injury Table (“Table”) and the Qualifications and Aids to
Interpretation (“QAI”), which afford petitioner a presumption of causation if the onset of
GBS occurs between three and forty-two days after a seasonal flu vaccination and there
is no apparent alternative cause.” Id. at 6.
In view of Respondent’s position and the evidence of record, I find that
Petitioner is entitled to compensation.
IT IS SO ORDERED.
s/Brian H. Corcoran
Brian H. Corcoran
Chief Special Master
2

================================================================================
DOCUMENT 2: USCOURTS-cofc-1_22-vv-00879-2
Date issued/filed: 2024-07-08
Pages: 12
Docket text: PUBLIC DECISION (Originally filed: 04/29/2024) regarding 41 DECISION of Special Master ( Signed by Chief Special Master Brian H. Corcoran. )(mpj) Service on parties made.
--------------------------------------------------------------------------------
Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 1 of 12
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 22-0879V
J.S., Chief Special Master Corcoran
Petitioner, Filed: April 29, 2024
v. Re-filed as Redacted: July 2, 2024
SECRETARY OF HEALTH AND
HUMAN SERVICES,
Respondent.
Elizabeth Kyla Abramson, Maglio Christopher & Toale, P.A., Washington, DC, for
Petitioner.
Sarah Black Rifkin, U.S. Department of Justice, Washington, DC, for Respondent.1
DECISION AWARDING DAMAGES2
On August 10, 2022, J.S. filed a petition for compensation under the National
Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.3 (the “Vaccine
Act”). Petitioner alleges that he suffered Guillain-Barré syndrome (“GBS”) resulting from
an influenza (“flu”) vaccine received on October 3, 2020. Petition at 1-11. The case was
assigned to the Special Processing Unit (“SPU”) of the Office of Special Masters.
1 Shelly Jock appeared for Respondent at the April 26, 2024 Motions Day hearing.
2 When this Decision was originally filed, I advised my intent to post it on the United States Court of Federal
Claims' website, and/or at https://www.govinfo.gov/app/collection/uscourts/national/cofc, in accordance
with the E-Government Act of 2002. 44 U.S.C. § 3501 note (2018) (Federal Management and Promotion
of Electronic Government Services). In accordance with Vaccine Rule 18(b), Petitioner filed a timely motion
to redact certain information. This decision is being posted with Petitioner’s name redacted to reflect his
initials only. Except for those changes and this footnote, no other substantive changes have been made.
This Decision will be posted on the court’s website and/or
at https://www.govinfo.gov/app/collection/uscourts/national/cofc with no further opportunity to move for
redaction.
3 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease
of citation, all section references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C.
§ 300aa (2018).

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 2 of 12
For the reasons set forth below, I find that Petitioner is entitled to an award of
damages in the amount of $189,510.57, comprised of $178,000.00 for actual pain and
suffering, $6,828.80 in lost earnings, and $4,681.77 in unreimbursable expenses.
I. Relevant Procedural History
The case was activated on September 15, 2022 (ECF No. 10). Respondent
conceded entitlement, and the parties entered into damages negotiations (ECF Nos. 23-
28). However, they reached an impasse (ECF No. 29). On July 17, 2023, Petitioner filed
a motion for a ruling on the record addressing damages (ECF No. 31). Respondent reacted
(ECF No. 34), and Petitioner replied (ECF No. 35).
On March 25, 2024, the parties filed a joint status report confirming that they were
amenable to an expedited hearing on “Motions Day,” and were available for this purpose
on April 26, 2024 (ECF No. 40). The Motions Day hearing occurred as scheduled on April
26, 2024, and this written decision memorializes my oral ruling issued at the conclusion
of the hearing.4
II. Relevant Factual Evidence
A. Medical Records
Petitioner had a pre-vaccination medical history of diabetes, hypertension,
hyperlipidemia, and erectile dysfunction. Ex. 10 at 125; Ex. 14 at 231. On October 3,
2020, Petitioner, then 66 years old, received flu and pneumococcal vaccines in his left
deltoid. Ex. 1. Ten days later, he went to the emergency department, reporting a two day
history of ascending weakness. Ex. 4 at 29. He had awoken the day before with
numbness in both feet and was weak “all over,” with the numbness and weakness
becoming progressively worse. Id. He had been falling at home and could not ambulate.
Id. On examination, he had bilateral lower extremity weakness and absent patellar
reflexes. Id. at 33. A CT scan of his brain was done, and a lumbar puncture was attempted
four times without success in the emergency department. Id. at 33, 42, 43. He was
admitted to the intensive care unit with concern for GBS. Id. at 99-100.
A repeat lumbar puncture the next day (October 14, 2020) was successful and
revealed elevated protein. Ex. 4 at 18, 171. His neurologist, Dr. James Fleming,
determined that Petitioner’s history, clinical exam, and lumbar puncture results were
4 That ruling will be set forth in the transcript from the hearing, which has not yet been filed but is fully
incorporated into this Decision.
2

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 3 of 12
consistent with acute demyelinating polyneuropathy, a form of GBS, and ordered IVIG.
Id. at 143. An MRI of his cervical spine was attempted, without success. Id. at 183.
Petitioner remained hospitalized for eleven days. Ex. 4 at 101. He was treated with
gabapentin and five days of IVIG, with some improvement. Id. at 102, 166. Even after
completing IVIG, he continued to be very weak and have severe back pain. Id. at 221. He
had significant pain and weakness in his upper and lower extremities that was well-
controlled with opiates for a time. Id. at 102. However, he developed colonic distention
and an ileus, resulting in decompression via nasogastric and rectal tubes, and opiates
were therefore stopped. Id. at 102, 246, 254, 269. He was discharged to inpatient
rehabilitation for continued strengthening. Id.
Petitioner remained in inpatient rehabilitation for 32 days, from October 24 to
November 25, 2020. Ex. 3 at 209. On admission, he had moderate impairment in upper
extremity coordination, severe impairment in lower extremity coordination, and severe
impairment in his shoulder range of motion. Id. at 219. After several adjustments,
adequate pain control was achieved. Id. at 210. He did physical, occupational, and
speech therapy. Id. He was discharged home in stable condition on November 25, 2020.
Id.
After going home, Petitioner continued care with his primary care physician, Dr.
Martha Ziegler, for lingering effects of GBS and other health concerns. Ex. 10 at 56. On
December 4, 2020, he still felt decreased strength and sensation in his lower and upper
extremities. Id. at 58. He was advised to continue physical therapy (“PT”) on an outpatient
basis. Id. at 59.
Petitioner continued outpatient PT and occupational therapy for nearly two months
and was discharged on January 20, 2021, with instructions to continue exercises at home.
Ex. 3 at 263-67. At discharge, he was “a whole lot better.” Id. at 263. A month earlier, he
had been afraid he would never walk again. Id. Now, his main problem was balance,
burning pain in his feet and fingers, and difficulty sleeping. Id. He showed improvement
in standing and stepping over items, but had difficulty getting up from low surfaces. Id. He
reported tingling pain in his feet and fingertips ranging from two to six out of ten. Id. at
264. On examination, he had normal range of motion but reduced strength in his hip,
knee, and ankle/foot. Id. He was assessed with “[m]uch improved balance and mobility
as evidenced by outcome measures.” Id. at 266. He had met six out of seven treatment
goals, and was determined not to need further skilled PT. Id.
A month later (February 23, 2021), Petitioner saw Dr. Ziegler reporting that he had
fallen a week earlier, landing on his right hip on a hard floor. Ex. 10 at 38. He reported a
pain level of two out of ten. Id. He had self-treated with acetaminophen, ice, and elevation,
with moderate relief. Id. On examination, his right hip had a four centimeter hematoma
and was mildly tender to palpation. Id. at 40. Dr. Ziegler recommended that he rest, apply
heat, and take Tylenol as needed for pain. Id.
3

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 4 of 12
Petitioner saw neuromuscular specialist Dr. Joshua Alpers on March 5, 2021 for
an evaluation and electrodiagnostic testing. Ex. 6 at 4-5. Petitioner was not experiencing
overt sensory loss, but continued to have paresthesias in both hands and feet, as well as
upper extremity weakness, poor balance, and falls. Id. at 4. On examination, he had
reduced sensation. Id. at 5. Dr. Alpers performed an EMG and nerve conduction study.
Id. The results were abnormal, with evidence of sensorimotor polyneuropathy consistent
with resolving GBS. Id. Dr. Alpers did not think the results suggested chronic
demyelinating polyneuropathy or premorbid diabetic neuropathy. Id.
Dr. Ziegler cleared Petitioner to return to work with a restriction of no lifting greater
than five pounds on March 29, 2021. Ex. 10 at 6-10. Petitioner was still on Gabapentin,
and was able to walk with a cane and do all usual activities of daily living. Id.
Petitioner returned to Dr. Ziegler on June 17, 2021 for fatigue, numbness, and
weakness. Ex. 15 at 117. On examination, his coordination and gait were normal, but he
exhibited motor weakness, sensory deficits, and abnormal reflexes. Id. at 118. Dr. Ziegler
discussed the long term effects of GBS and advised Petitioner to continue exercise, rest,
and increased fluids. Id. at 119.
On October 12, 2021, Petitioner saw urologist Dr. Anand Shridharani. Ex. 14 at
230. His erectile dysfunction had previously been responsive to medication, but after his
GBS hospitalization this was no longer the case. Id. at 71, 231. As a result, he underwent
surgical implantation of an inflatable penile prosthesis on December 13, 2021. Id. at 47.
By March 2022, Petitioner was doing well with no restrictions. Ex. 16 at 7.
Petitioner saw Dr. Ziegler on April 28, 2022. Ex. 20 at 28. He had numbness in his
feet, which Dr. Ziegler attributed to diabetic neuropathy. Id.at 30. Petitioner saw Dr.
Ziegler again two months later (June 28, 2022) for an annual physical. Id. at 6. Petitioner
reported that he still had some weakness in his arms and legs from GBS. Id. at 7. On
examination he had motor weakness and sensory deficits, with normal gait, coordination,
and reflexes. Id. at 9.
B. Declarations
Petitioner submitted three declarations in support of his claim. Exs. 12, 18, 28. In
them he notes that he began feeling tingling and burning in his hands and feet, and feeling
off-balance, nine days after vaccination. Ex. 18 at ¶ 2. The next day, he tried to get out of
bed but fell and could not get back up. Id. at ¶ 3. His daughter and son in law came and
helped him up, and took him to the hospital. Id.
By the time he was diagnosed with GBS, his “entire body was burning and tingling.”
Ex. 18 at ¶ 6. He was in horrible pain and could not walk or even roll over in bed. Id. He
4

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 5 of 12
described the pain as “like being burnt all over my body,” and it was bad enough to make
him “want to die.” Id.
He recalled a situation that occurred while he was in the intensive care unit of the
hospital. He needed to use the restroom, but his call button was not working, and he could
not get himself to the bathroom. Ex. 18 at ¶ 7. He soiled himself, and was left to lay in it
for hours. Id. While he was hospitalized, visitors were limited due to the COVID-19
Pandemic; as a result, he was alone most of the time, which made it even worse. Id. at
¶ 8.
He has worked hard to recover from GBS. Ex. 18 at ¶ 9. In June 2021, he began
working with a personal trainer at a gym, who researched GBS and designed an exercise
plan to help Petitioner get stronger and improve his balance. Id.
Before his GBS, Petitioner enjoyed fly fishing, hunting, and training his “squirrel
dogs.” Ex. 18 at ¶ 10. He spent a lot of time outdoors in the woods and mountains, and
was independent and active in his hobbies, work, and home. Id. Now, he has trouble
feeling his feet, and has to be careful when walking to make sure he picks up his feet so
he does not trip. Ex. 28 at ¶ 2. Because of these residual symptoms, he is no longer
comfortable going out into the woods or fishing alone. Id. at ¶ 3.
Petitioner feels like he has lost his independence because of his GBS. Ex. 18 at
¶ 12. When he was discharged from the inpatient rehabilitation hospital, he had to live
with his brother for four months, and needed family to take care of his dogs and drive him
to appointments. Id. His left arm remains much weaker than his right arm. Id. at ¶ 13. His
legs remain weak and cause problems, such as difficulty squatting to look at items on low
shelves in a store. Id. at ¶ 15. He recalled a situation when he was at a hardware store
looking at an item on the bottom shelf. Id. To read the details on the item, he had to sit on
the floor, but then was unable to stand back up on his own and had to call his brother to
come and help him. Id.
Petitioner tried walking on a treadmill to strengthen his legs, but his left leg kept
giving out. Ex. 18 at ¶ 16. He recalled that one time he was on the treadmill and fell, and
was flung back into a woman who had been walking behind the treadmill. Id. In the
process, he knocked her down, and both Petitioner and the woman were hurt. Id. He
stopped using the treadmill after that. Id.
His leg and feet symptoms worry and scare him. Ex. 18 at ¶ 17. When he gets
stuck sitting on the floor, it is frightening because he doesn’t know if or when someone
will help him up. Id. It embarrasses him to need help getting up, especially in public. Id.
Although his overall health has improved, he is not back to his pre-GBS baseline.
Ex. 28 at ¶ 2. He estimates that he has lost about two thirds of his strength due to GBS,
with his left arm being particularly weak. Id. at ¶ 4. He continues to have trouble returning
to standing from a low squat due to weakness. Id. He continues to have double vision
5

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 6 of 12
from GBS, and now needs special glasses to correct it. Id. at ¶ 5. He continues to take
gabapentin for nerve pain at times. Id. at ¶ 7. Petitioner also worries about getting the flu
or covid, since he is high risk due to age, and has been advised not to get more vaccines.
Ex. 18 at ¶ 20. He has tried to maintain a positive attitude, but his life now is very different
than it was before GBS. Id. at ¶ 21.
In addition, Petitioner had erectile dysfunction prior to GBS, but it responded to
medication. Ex. 18 at ¶ 18. After his GBS, however, his condition no longer responded to
medication. Id. His doctor told him this was likely due to nerve damage. Id. As a result,
he had an implant surgically placed to address his erectile dysfunction. Id. at ¶ 19.
However, he states he is having problems with the implant, and always worries whether
it will work or not, and lately has been having problems with the release valve. Id. This
has been embarrassing, and he is having a hard time dealing with this emotionally. Id. He
has remarried, and is not comfortable talking with his wife about his surgery to correct
erectile dysfunction. Ex. 28 at ¶ 6. On the positive side, his experience with GBS has
strengthened his faith and relationships and motivated him to take care of his body,
resulting in significant improvements in his diabetes. Id. at ¶ 8.
When Petitioner was first diagnosed with GBS, he was unable to work for about
five months. Ex. 28 at ¶ 9. He had a lot of accrued sick leave, which he used, and thus
he continued receiving a paycheck. Id. However, using that sick leave meant that he lost
a significant number of creditable service hours that would have factored into the monthly
payments he receives when he retires (which he plans to do around June 2024). Id. at
¶¶ 9, 11.
III. Legal Standard
Compensation awarded pursuant to the Vaccine Act shall include “[f]or actual and
projected pain and suffering and emotional distress from the vaccine-related injury, an
award not to exceed $250,000.” Section 15(a)(4). Additionally, a petitioner may recover
“actual unreimbursable expenses incurred before the date of judgment award such
expenses which (i) resulted from the vaccine-related injury for which petitioner seeks
compensation, (ii) were incurred by or on behalf of the person who suffered such injury,
and (iii) were for diagnosis, medical or other remedial care, rehabilitation . . . determined
to be reasonably necessary.” Section 15(a)(1)(B). The petitioner bears the burden of proof
with respect to each element of compensation requested. Brewer v. Sec’y of Health &
Human Servs., No. 93-0092V, 1996 WL 147722, at *22-23 (Fed. Cl. Spec. Mstr. Mar. 18,
1996).
There is no mathematic formula for assigning a monetary value to a person’s pain
and suffering and emotional distress. I.D. v. Sec’y of Health & Human Servs., No. 04-
1593V, 2013 WL 2448125, at *9 (Fed. Cl. Spec. Mstr. May 14, 2013) (“[a]wards for
emotional distress are inherently subjective and cannot be determined by using a
6

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 7 of 12
mathematical formula”); Stansfield v. Sec’y of Health & Human Servs., No. 93-0172V,
1996 WL 300594, at *3 (Fed. Cl. Spec. Mstr. May 22, 1996) (“the assessment of pain and
suffering is inherently a subjective evaluation”). Factors to be considered when
determining an award for pain and suffering include: 1) awareness of the injury; 2) severity
of the injury; and 3) duration of the suffering. I.D., 2013 WL 2448125, at *9 (quoting
McAllister v. Sec’y of Health & Human Servs., No 91-1037V, 1993 WL 777030, at *3 (Fed.
Cl. Spec. Mstr. Mar. 26, 1993), vacated and remanded on other grounds, 70 F.3d 1240
(Fed. Cir. 1995)).
I may also consider prior pain and suffering awards to aid my resolution of the
appropriate amount of compensation for pain and suffering in this case. See, e.g., Doe
34 v. Sec’y of Health & Human Servs., 87 Fed. Cl. 758, 768 (2009) (finding that “there is
nothing improper in the chief special master’s decision to refer to damages for pain and
suffering awarded in other cases as an aid in determining the proper amount of damages
in this case.”). And, of course, I may rely on my own experience (along with my
predecessor Chief Special Masters) adjudicating similar claims.5 Hodges v. Sec’y of
Health & Human Servs., 9 F.3d 958, 961 (Fed. Cir. 1993) (noting that Congress
contemplated the special masters would use their accumulated expertise in the field of
vaccine injuries to judge the merits of individual claims).
IV. The Parties’ Arguments
A. Pain and Suffering
Petitioner proposes an award comprised of pain and suffering, lost earnings, and
out of pocket expenses. Petitioner’s Motion for Damages, filed July 17, 2023, at *8 (ECF
No. 31) (“Mot.”). The parties agree that Petitioner is entitled to $6,828.80 in lost wages,
and $3,644.49 for out-of-pocket expenses exclusive of mileage. Petitioner’s Reply, filed
Oct. 5, 2023, at *1 (ECF No. 35) (“Reply”). The parties’ disagreement on damages is
limited to two matters: (1) the amount of damages for pain and suffering, and (2) whether
Petitioner’s travel expenses for his medical treatment should be reimbursed at the IRS
mileage rate for business travel, as Petitioner proposes, or the medical rate, as
Respondent suggests.
Petitioner proposes a pain and suffering award of $180,000.00, citing Clemens,
Hood, McCray, Devlin, and Presley.6 Mot. at *10-19. At the Motions Day hearing,
5 From July 2014 until September 2015, the SPU was overseen by former Chief Special Master Vowell. For
the next four years, until September 30, 2019, all SPU cases, including the majority of GBS claims, were
assigned to former Chief Special Master Dorsey. In early October 2019, the majority of SPU cases were
reassigned to me as the current Chief Special Master.
6 Clemens v. Sec’y of Health & Human Servs., No. 19-1547V, 2022 WL 2288515 (Fed. Cl. Spec. Mstr. May
17, 2022) ($180,000.00 awarded for actual pain and suffering); Hood v. Sec’y of Health & Human Servs.,
No.16-1042V, 2021 WL 5755324 (Fed. Cl. Spec. Mstr. Oct. 19, 2021) ($200,000.00 awarded for actual pain
7

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 8 of 12
Petitioner cited Ruppert,7 which was decided after this case was briefed. Petitioner
emphasizes that he was hospitalized for 11 days and spent 32 days in an inpatient
rehabilitation facility, underwent a five-day course of IVIG, treated with gabapentin and
opioids for pain, and treated with physical and occupational therapy. Id. at *11. During
treatment, he developed an ileus, requiring placement of a rectal tube and discontinuation
of opioids. Id.
When Petitioner was discharged, he was unable to return to his own home, instead
living with his brother for four months. Mot. at *11. He then participated in 12 sessions of
PT and nine sessions of occupational therapy on an outpatient basis. Reply at *4 n. 2.
Despite the extensive therapy, he continued to experience residual numbness and
weakness, resulting in frequent falls and some injuries. Mot. at *12. He relied on a cane
to walk. Id. He estimates he has lost two thirds of his strength due to GBS, and continues
to have difficulty picking up objects with his left arm and getting up from a low squat. Id.
Because of continued difficulty feeling his feet, he has to walk with care to avoid tripping,
and has had to curtail and alter his lifestyle and hobbies. Id. at *12-13. His GBS
exacerbated his pre-existing erectile dysfunction, resulting in a surgical procedure, which
has been embarrassing and emotionally difficult. Id. at *13.
Petitioner argues that he was of a similar age as the petitioners in McCray, Devlin,
and Presley. Mot. at *17. He had a history of neuropathic symptoms, like the McCray and
Presley petitioners. Id. Petitioner lived independently in a rural area, like the Presley
petitioner. Id. Petitioner’s hospitalization was similar in duration to that of the petitioner in
Devlin, but Petitioner’s inpatient rehabilitation stay was far longer than that of any of the
petitioners in the cases he cites. Id. at *18. Petitioner endured several failed lumbar
puncture attempts, like the Presley petitioner. Id.
Overall, Petitioner contends, he experienced a moderately severe course of GBS.
Reply at *2-3. Petitioner emphasizes the length of his hospital and inpatient rehabilitation
stay, diagnostic testing, treatment with IVIG, gabapentin, opioids, PT, and occupational
therapy, as well as his ileus complication and exacerbation of his erectile dysfunction. Id.
at *3-4. More broadly, prior to his GBS, Petitioner lived an active, independent lifestyle,
which was curtailed by his GBS. Id. at *5. Petitioner experienced severe pain, fear,
and suffering, in addition to $1,000.00 per year for future pain and suffering); McCray v. Sec’y of Health &
Human Servs., No.19-0277V, 2021 WL 4618549 (Fed. Cl. Spec. Mstr. Aug. 31, 2021) ($180,000.00
awarded for actual pain and suffering); Devlin v. Sec’y of Health & Human Servs., No. 19-0191V, 2020 WL
5512505 (Fed. Cl. Spec. Mstr. Aug. 7, 2020) ($180,000.00 awarded for actual pain and suffering); and
Presley v. Sec’y of Health & Human Servs., No. 17-1888V, 2020 WL 1898856 (Fed. Cl. Spec. Mstr. Mar.
23, 2020) ($180,000.00 awarded for actual pain and suffering).
7 Ruppert v. Sec’y of Health & Human Servs., No. 18-1621V, 2023 WL 9063679 (Fed. Cl. Spec. Mstr. Nov.
30, 2023) ($180,000.00 awarded for actual pain and suffering).
8

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 9 of 12
anxiety, and embarrassment during four failed lumbar puncture attempts, several
unsuccessful MRIs, and placement of a rectal tube. Id.
In Petitioner’s view, Respondent also fails to give proper weight to the GBS
sequelae Petitioner continued to experience after hospitalization, apparently due to
Respondent not considering Petitioner’s declarations. Reply at *6. Petitioner takes issue
with Respondent’s reliance on proffered cases, noting that the court has admonished
Respondent for doing so on numerous occasions. Id. at *8 (citing Felland v. Sec’y of
Health & Human Servs., No. 20-406V, 2022 WL 10724100, at *3 (Fed. Cl. Spec. Mstr.
Sept. 6, 2022), and Sakovits v. Sec’y of Health & Human Servs., No. 17-102V, 2020 WL
3729420), at *4 (Fed. Cl. Spec. Mstr. June 4, 2020)).
Petitioner acknowledges that his cited cases are not identical to his, but asserts
that is “hardly surprising given the complexity of neurologic disorders and the individual
circumstances that influence not only one’s clinical course, but ability to adapt one’s
lifestyle to the limitations imposed by the condition.” Reply at *9-10. Petitioner agrees that
a higher award was warranted in Hood, which he has acknowledged by requesting a
lower sum than awarded in that case. Id. at *11 n.3.
Respondent proposes a pain and suffering award of $135,000.00. Respondent’s
Brief on Damages, filed Sept. 28, 2023, at *6-10 (ECF No. 34) (“Resp.”). Respondent
argues that Petitioner’s clinical course and treatment demonstrate a less severe course
of GBS compared to other cases. Id. at *7. Respondent emphasizes that Petitioner was
hospitalized for 11 days and inpatient rehabilitation for another 31 days, with a single
round of IVIG therapy for five days. Id. After discharge, Respondent asserts that Petitioner
attended only ten outpatient sessions of PT or occupational therapy and was discharged
with a good prognosis. Id. Respondent views as significant that the majority of Petitioner’s
care occurred during the immediate three months after his GBS diagnosis and
hospitalization. Id. at *8.
Respondent argues that five months after his GBS diagnosis, Petitioner was
cleared to return to work and was able to perform his daily life activities. Resp. at *8. After
this, he had very little GBS-related medical care. Id. Petitioner did not seek further
neurological care, and his later primary care visits were for his pre-existing diabetes. Id.
His December 2021 penile prosthesis surgery addressed a pre-existing problem that
required different care after his GBS. Id. And while Petitioner continued to experience
numbness in his feet, by April 2022 Dr. Ziegler attributed this to his diabetic neuropathy.
Id.
Respondent further maintains that Petitioner’s case was less severe than any of
the cited cases. Resp. at *8-10. However, Respondent does not cite any reasoned GBS
damages decision in support of his proposed award, referencing instead only three
proffered cases, Drapiewski v. Sec’y of Health & Human Servs., No. 21-1296V (Fed. Cl.
Spec. Mstr. Nov. 23, 2022); Schmidt v. Sec’y of Health & Human Servs., No. 17-913V
9

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 10 of 12
(Fed. Cl. Spec. Mstr. Apr. 30, 2019), and Mickles v. Sec’y of Health & Human Servs., No.
19-2012V (Fed. Cl. Spec. Mstr. March 2, 2021). Resp. at *10.
B. Mileage Rate for Travel Expenses Related to Vaccine Injury
Petitioner requests $1,037.28 for vaccine-related travel expenses, while
Respondent proposes that $299.13 should be awarded for this mileage. Reply at *11;
Resp. at *14.
Petitioner asserts that the IRS “business rate” is the appropriate reimbursement
rate for mileage. Mot. at *10, Reply at *11-16. Petitioner argues that Congress did not
provide specific direction as to how, or whether, IRS rates were to be applied in the
Vaccine Program. Reply at *14. Rather, Congress gave special masters wide discretion
to determine the appropriate amount of compensation to be awarded. Id. The use of IRS
rates “is in no way required of special masters” – but can allow special masters to quickly
and easily determine the full amount of compensation allowed for mileage expenses
incurred by petitioners. Id.
Petitioner argues that Respondent’s argument that fixed costs – which are
accounted for in the “business rate” but not the “medical rate” – do not result from a
vaccine injury fails to take into account that driving a vehicle more frequently means that
tire changes, repairs, and maintenance will be needed more frequently, and will lower the
vehicle’s trade in value. Reply at *14-15. Thus, Petitioner argues that it is reasonable to
compensate petitioners for both the variable and fixed costs of vehicle operation –
because both are incurred when driving to and from treatment for a vaccine injury. Id. at
*15. Petitioner argues that allowing the business rate is not “optimizing,” or providing an
overly generous award. Id. Rather, the business rate is a standard rate that is based on
the average cost of operating a vehicle. Id.
Respondent contends that the IRS “medical rate” is the appropriate rate for
calculation of Petitioner’s travel expenses related to medical appointments for his vaccine
injury. Resp. at *11. Respondent argues that the special master in Williams v. Sec’y of
Health & Human Servs., No. 90-2239V, 1996 WL 608455 (Fed. Cl. Spec. Mstr. Oct. 10,
1996) applied the IRS “business rate” rather than the “medical rate,” and that special
masters have subsequently relied on Williams and applied the business rate. Id. In his
view, the reasoning of Williams is flawed, and urges that I decline to follow it and apply
the lower medical rate. Resp. at *12.
V. Appropriate Compensation in this Case
A. Pain and Suffering
Awarding damages is more of an art than a science. In arriving at an award, I
review the facts and circumstances of the petitioner before me, in the context of other
cases and precedent. GBS is a particularly concerning and frightening condition, and the
10

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 11 of 12
pain and suffering award should reflect that. Reasoned decisions, rather than cases
resolved on proffer, provide the best comparable cases for arriving at an award when the
parties are unable to resolve damages through negotiations.
In this particular case, Petitioner had a moderate case of GBS. Initially he was
hospitalized in the intensive care unit, after which he was in an inpatient rehabilitation
facility for a month. In the hospital, it took five attempts to successfully complete a lumbar
puncture that confirmed his diagnosis. He experienced complications from pain
medications that resulted in additional procedures. When he was discharged, he could
not live independently and had to go to his brother’s home rather than his own home.
However, he was able to return to his job (with restrictions) just under six months after his
illness began.
Although his remaining symptoms and abnormal test results were most apparent
in the five months following onset, he continued to experience documented residual
effects of his GBS for much longer, including a surgical procedure at fourteen months for
his pre-existing erectile dysfunction that no longer responded to prior treatment. Twenty
months after onset, he continued to have motor weakness and sensory deficits. Ex. 20 at
9. I find that Petitioner’s proposed award is better supported by the record and applicable
precedent (as I have repeatedly noted that proffers provide poor guidance), and award
Petitioner $178,000.00 for actual pain and suffering.
B. Unreimbursable Expenses and Mileage Rate for Travel Expenses
Related to Vaccine Injury
The parties agree on most unreimbursable expenses, as noted, but dispute the
rate to be applied for Petitioner’s travel related to these expenses I have addressed this
question, and Respondent’s arguments on the matter, in several recent decisions. Walter
v. Sec’y of Health & Human Servs., No. 21-1461V, 2024 WL 1299576 (Fed. Cl. Spec.
Mstr. Feb. 27, 2024); Tappendorf v. Sec’y of Health & Human Servs., No. 20-1592V, 2024
WL 1299566 (Fed. Cl. Spec. Mstr. Feb. 23, 2024); Kleinschmidt v. Sec’y of Health &
Human Servs., No. 20-0680V, 2023 WL 9119039 (Fed. Cl. Spec. Mstr. Dec. 5, 2023);
Gibson v. Sec’y of Health & Human Servs., No. 20-0243V, 2022 WL 17820891 (Fed. Cl.
Spec. Mstr. Oct. 5, 2022).
In short, despite Respondent’s views of Williams, I have embraced its holding as
more in sync with the remedial goals of the Program (awarding petitioners their actual
unreimbursable expenses – which includes not just the operating costs of a vehicle, but
also the fixed costs that the “business rate” takes into consideration). Tappendorf, 2024
WL 1299566, at *6. As such, application of the business rate results in a reasonable
award – not an “optimized” award, as Respondent contends. Accordingly, I award
reimbursement for travel expenses related to Petitioner’s agreed-upon out-of-pocket
expenses at the “business rate.” This results in an award of $4,681.77 for Petitioner’s
11

Case 1:22-vv-00879-UNJ Document 53 Filed 07/08/24 Page 12 of 12
unreimbursed expenses (the agreed-upon expenses of $3,644.49, plus mileage
expenses of $1,037.28).
Conclusion
For all of the reasons discussed above and based on consideration of the record
as a whole, I find that $178,000.00 represents a fair and appropriate amount of
compensation for Petitioner’s actual pain and suffering.8 I also find that Petitioner
is entitled to $4,681.77 in actual unreimbursable expenses and $6,828.80 for lost
wages.
I therefore award Petitioner a lump sum payment in the amount of
$189,510.57 in the form of a check payable to Petitioner. This amount represents
compensation for all damages that would be available under Section 15(a).
The Clerk of the Court is directed to enter judgment in accordance with this
Decision.9
IT IS SO ORDERED.
s/Brian H. Corcoran
Brian H. Corcoran
Chief Special Master
8 Since this amount is being awarded for actual, rather than projected, pain and suffering, no reduction to
net present value is required. See Section 15(f)(4)(A); Childers v. Sec’y of Health & Human Servs., No. 96-
0194V, 1999 WL 159844, at *1 (Fed. Cl. Spec. Mstr. Mar. 5, 1999) (citing Youngblood v. Sec’y of Health &
Human Servs., 32 F.3d 552 (Fed. Cir. 1994)).
9 Pursuant to Vaccine Rule 11(a), entry of judgment can be expedited by the parties’ joint filing of notice
renouncing the right to seek review.
12